Prevalence of spondyloarthritis in inflammatory bowel disease according ASAS and ultrassonography and its correlation with plasma calprotectin

• Published in: Advances in rheumatology (London, England) Vol. 64; no. 1; pp. 27 - 11
• Main Authors: Huber, Míriam Küster, Valim, Valeria, Serrano, Érica Vieira, Mendonça, José Alexandre, Lourenço, Rafael Burgomeister, Espírito Santo, Thaisa Moraes Ribeiro, Nordal, Hilde, de Fátima Bissoli, Maria, de Oliveira Gavi, Maria Bernadete Renoldi
• Format: Journal Article
• Language: English
• Published: England Sociedade Brasileira de Reumatologia 15-04-2024; BMC
• Subjects: ASAS; Biomarkers; Calprotectin; Cohort Studies; Cross-Sectional Studies; Humans; Inflammatory bowel disease; Inflammatory Bowel Diseases - complications; Inflammatory Bowel Diseases - diagnostic imaging; Inflammatory Bowel Diseases - epidemiology; Musculoskeletal ultrasonography; Prevalence; RHEUMATOLOGY; Spondylarthritis - diagnostic imaging; Spondylarthritis - epidemiology; Spondyloarthritis; Synovitis; Tenosynovitis; Inflammatory bowel disease; ASAS; Calprotectin; Musculoskeletal ultrasonography; Spondyloarthritis
• ISSN: 2523-3106; 2523-3106
• DOI: 10.1186/s42358-023-00348-6

Enteropathic spondyloarthritis is underdiagnosed and inflammatory biomarkers and ultrasonography (US) could be useful for screening inflammatory bowel disease (IBD) patients. The objective of this study was to evaluate the prevalence of spondyloarthritis (SpA) in IBD patients, according to the Assessment of SpondyloArthritis International Society (ASAS) criteria and the correlation of results of US of entheses and joints with plasma calprotectin levels.
This was an observational cross-sectional study. Patients from the IBD outpatient clinic of a reference center were evaluated according to ASAS criteria classification, results of US of entheses and joints, and inflammatory biomarker measurements (erythrocyte sedimentation rates, C-reactive protein levels, fecal and plasma calprotectin levels). A p value lower than 0.05 was considered significant.
A total of 30.5% of the studied sample (n = 118) of patients with IBD presented at least one inflammatory musculoskeletal manifestation. The overall prevalence of enteropathic SpA was 13.55%, with 10.16% axial SpA and 4.23% peripheral SpA according to the ASAS criteria. A total of 42.1% of patients had an MASEI score greater than 18, 35.2% had synovitis, and 14.7% had tenosynovitis on US, increasing the frequency of diagnosis of enteropathic SpA to 22.8%. Plasma calprotectin levels were similar to those in healthy controls, and correlated only with the fecal calprotectin level (p 0.041).
A total of 13.5% of patients met the criteria in accordance with the ASAS criteria for enteropathic SpA, which increased to 22.8% with the addition of US. The prevalence of enthesitis, synovitis and tenosynovitis by US of symptomatic joints and entheses were 42%, 35% and 14.7% respectively. Plasma calprotectin was correlated with fecal calprotectin but not with inflammatory biomarkers or US or ASAS criteria.